Genetic basis of drug‐induced arrhythmias

References

• Roden DM. Taking the idio out of idiosyncratic: predicting torsade de pointes. Pacing Clin Electrophysiol 1998;21:1029–34.
   Google Scholar
• Vos MA, van Opstal JM, Leunissen HDM, Verduyn SC. Electrophysiologic parameters and predisposing factors in the generation of drug induced Torsade de Pointes arrhythmias. Pharmacol Therap 2001;92:109–22.
   Google Scholar
• Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug induced Torsade de Pointes. Trends Pharmacol Sci 2003;24:619–25.
   Google Scholar
• Vos MA. Do we understand the electrophysiological mech-anisms responsible for drug induced cardiac arrhythmias? J Cardiovasc Pharmacol 2002;40:647–50.
   Google Scholar
• Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long QT syndrome. Clinical impact. Circulation 1999;99:529–33.
   Google Scholar
• Kubota T, Shimuzu W, Kamakura S, Hone M. Hypokalemia induced long QT syndrome with an underlying novel missence mutation in S4-S5 linker of KCNQ1. J Cardiovasc Electro-physiol 2000;11:1048–54.
   Google Scholar
• Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL, Goldstein SAN. A common polymorphism associated with anti-biotic induced cardiac arrhythmias. Proc Natl Acad Sci USA 2000;97:175–87.
   Google Scholar
• Yang P, Kanki H, Drolet B, Yang B, Wei J, Viswanathan PC, et al. Allelic variants in long QT disease genes in patients with drug associated Torsade de Pointes. Circulation 2002; 105: 1943–8.
   Google Scholar
• Chevalier P, Rodriguez C, Bontemps L, Miguel M, Kirkorian G, Rousson R, et al. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc Res 2001;50:386–98.
   Google Scholar
• Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002; 297: 1333–6.
   Google Scholar
• Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, et al. KvLQT1 C-terminal missense mutation cause a forme fruste long QT syndrome. Circulation 1997;96: 2778–81.
   Google Scholar
• Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, et al. MiRP1 forms Ikr potassium channels with HERG and is associated with cardiac arrhythmias. Cell 1999;97:175–87.
   Google Scholar
• Piquette RK. Torsade de Pointes induced by cisapride/clari-thromycin interaction. Ann Pharmacother 1999;33:22–6.
   Google Scholar
• Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, et al. Evidence for a cardiac ion channel mutation underlying drug induced QT prolongation and life threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 107:499–503.
   Google Scholar
• Piippo K, Holmstrom S, Swan H, Viitasalo M, Raatikka M, Toivonen L, et al. Effect of the antimalarial drug halofantrine in the long QT syndrome due to a mutation of the cardiac sodium channel gene SCN5A. Am J Cardiol 2001;87:909–11.
   Google Scholar
• Makita N, Hone M, Nakamura T, Ai T, Sasaki K, Yokoi H, et al. Drug induced long QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002;106:1269–74.
   Google Scholar
• Paulussen ADC. Genetic variations involved in congenital and acquired long QT syndrome. PhD Thesis University Maas-tricht, 2003 (ISBN 90-9016744–7).
   Google Scholar
• Nattel S. Acquired delayed rectifier channelopathies: how heart disease and antiarrhythmic drug mimic potentially lethal congenital cardiac disorders. Cardiovasc Res 2000;48:188–90.
   Google Scholar
• Kanki H, Yang P, Xie HG, Kim RB, George AL, Roden DM. Polymorphisms in beta adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol 2002;13:252–6.
   Google Scholar
• Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-phar-macodynamic consequences and clinical relevance of cyto-chrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38: 41–57.
   Google Scholar
• Guengerich FP. Cytochrome P450 3A4: regulation and rolein drug metabolism. Annu Rev Pharmacol Toxicol 1999;4:11–20.
   Google Scholar
• Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P450 (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999;27:180–7.
   Google Scholar
• Paulussen ADC, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, et al. Two linked variations in the transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity inhumans. Pharmacogenetics 2000;10:415–24.
   Google Scholar
• Volders PGA, Sipido KR, Vos MA, Spätjens RLHMG, Leunissen HDM, Carmeliet E, et al. Downregulation of delayed rectifier ICE current in dogs with chronic complete atrioventricular block and acquired Torsade de Pointes. Circulation 1999;100:2455–61.
   Google Scholar
• Ramakers C, Vos MA, Doevendans PA, Schoenmakers M, Wu YS, Scicchitano S, et al. Coordinated down-regulation of KCNQ1 and KCNE1 expression contributes to reduction in Iks in canine hypertrophied hearts. Cardiovasc Res 2003;57: 486–96.
   Google Scholar
• Kaab S, Hinterseer M, Nabauer M, Steinbeck G. Sotalol testing unmasks altered repolarisation in patients with suspected acquired long QT syndrome: a case controlled pilot study using i.v. sotalol. Eur Heart J 2003;24:649–57.
   Google Scholar
• Verduyn SC, Winckels SKG, Gorgels APM, Doevendans PA, Vos MA. Should class III drugs be initiated in hospital to prevent drug induced TdP arrhythmias. Neth J Cardiol. 2003; 11:70–6.
   Google Scholar